Assessment of ZnO and SiO₂ nanoparticle permeability through blood-brain barrier and their toxicity using Evans blue and TEM

Organization of research team for nano-associated safety assessment in effort to study nanotoxicology of zinc oxide and silica nanoparticles

Nov. 22th, 2014

Dr. Seong Soo A. An

Dept. of Bionano Technology



Needs: assessing toxicity of nanoparticles

Diverse commercial products with nanoparticles on the market











ZnO & SiO₂ NPs

20nm (+) charged

20nm (-) charged

100nm (+) charged

100nm (-) charged



Characterization of NPs

≻Selection of NPs by TEM images







➢ Preparing (−)charge NPs

<u>Candidates for (-)charge preparation</u>: **PAA** [Poly (acrylic acid)], **Citrate** [Sodium citrate]

<u>pH selection</u>∶ pH6, pH6.5, pH7

<u>Concentrations of Citrate</u> : Citrate buffer 1%, 2%, ZnO concentrations 10%, 20%, 100%



Dispersion, Distribution and Z-test

Dispersion of Serine treatedZnO NPs (HEPES pH6)

No ligand

352.5±114 nm







Grand Content of Cont

+ 25.46 mV

Dispersion, Distribution and Z-test

> ZnO: citrate(10:1), ddH2O, voltex 30s, No sonication,10min for settlement



537.3±237 nm





-39.64 mV





➤ (+)charged NPs

Candidates for (+)charging:

No ligand,

TREN [Tris (2-aminoethyl) amine], **PAH**, [Poly (allylamine hydrochloride)], **PDAC**, **DETA** [Diethylenetriamine], **Thiamine, Arginine, Lysine, Serine**

<u>pH selection</u>: pH6, pH6.5, pH7

<u>Concentrations of Serine</u>: Serine buffer: 1%, 2%, ZnO concentrations: 10%, 20%, 100%



Dispersion, Distribution and Z-test

+ Serine



543.4±261 nm

1% serine HEPES pH6





N	lo File Name	Repet. No	MeasTime	pH	Zeta Potential (mV)	Mobility (cm²/Vs)	E. Field (V/cm)
_	1 hepes_ph6-1_20100928_100724	1	10:07:24	NA	29.41	2.294e-004	15.42
	2 hepes_ph6-1_20100928_100724	2	10:07:24	NA	29.35	2.289e-004	15.42
	4 hepes_ph6-1_20100928_100724	4	10:07:24	NA	28.50	2.222e-004	15.43
_	Average				29.09	2.268e-004	15.42



+ 29.09 mV

Nanoparticles & Protein Corona



- Protein corona is likely to determine the fate of the nanomaterials *in vivo* (Cedervall *et al*, 2007).
- proteins can potentially interact with a nanomaterial to control its access to specific compartments, mark it for efficient removal by tissue-resident macrophages, and promote undesirable inflammation, thrombosis, and anaphylaxis (Peppas *et al*, 2006).







Protein corona SiO₂& ZnO NPs (- 20/100 nm)

Samples	Total (ZnO)	Total (SiO ₂)	Common
20 nm in plasma	58	48	9
100 nm in plasma	44	36	9
20 nm in BH	294	125	48
100 nm in BH	339	145	77



Unique plasma and BH proteins between SiO₂ 20 & 100 NPs

Plasma		Brain Homogenate	
20 nm	100 nm	20 nm	100 nm
hemopexin precursor, C4b- binding protein alpha chain, lipopolysaccharide-binding protein precursor, glyceraldehyde-3- phosphate dehydrogenase, inter-alpha-trypsin inhibitor heavy chain H3 precursor, T-kininogen 2 precursor, alpha-1-inhibitor 3 precursor, Serine protease inhibitor, ceruloplasmin precursor, Kallistatin, mast cell protease 9, serine protease inhibitor A3N, protein AMBP precursor,	Plasminogen, selenoprotein P precursor, vitronectin, alpha-1-antiproteinase precursor, plasma kallikrein precursor, kininogen-1 isoform 1, plasma protease C1 inhibitor precursor, apolipoprotein C-I precursor	calcium/calmodulin- dependent protein kinase, serine/threonine-protein phosphatase, histidine-rich glycoprotein, ATP- dependent RNA helicase A	pre-mRNA-processing- splicing factor 8, AP-2 complex subunit alpha-1, band 4.1-like protein 3, polyadenylate-binding protein 4, ADP- ribosylation factor 1, cytoplasmic dynein 1 heavy chain 1, kinesin heavy chain isoform 5C nucleolin

complement component C8 beta chain



Correlated plasma and BH proteins between SiO₂&ZnO NPs

Plasma			Brain Homogenate	
20 nm		100 nm	20 nm	100 nm
apolipoprotein precursor complement C complement C apolipoprotein complement C fibronectin pr PREDICTED glycoprotein- PREDICTED protein PREDICTED component 5 anionic trypsi PREDICTED glycoprotein-	n B-100 C3 component C9 n E precursor C4 precursor ecursor : histidine-rich like : hypothetical : complement n-1 precursor : histidine-rich like	apolipoprotein B-100 precursor complement C3 apolipoprotein E precursor PREDICTED: histidine-rich glycoprotein-like complement C4 precursor inter-alpha-inhibitor H4 heavy chain vitronectin fibronectin precursor plasma protease C1 inhibitor precursor PREDICTED: complement component 5 PREDICTED: histidine-rich glycoprotein-like	tubulin beta-3 chain, tubulin alpha-1A chain, clathrin heavy chain 1, synapsin-1 isoform b, glyceraldehyde-3- phosphate dehydrogenase, tubulin beta-2B chain, ATP synthase subunit alpha, mitochondrial precursor, dynamin-1, ATP synthase subunit beta, mitochondrial precursor, actin, aortic smooth muscle, heterogeneous nuclear ribonucleoprotein K, vesicle- fusing ATPase, elongation factor 1-alpha 2, V-type proton ATPase catalytic subunit A, actin,	tubulin beta-3 chain, tubulin alpha-1A chain, syntaxin- binding protein 1, vesicle- fusing ATPase, clathrin heavy chain 1, synapsin-1 isoform b, tubulin beta-2B chain, microtubule- associated protein 1B, glyceraldehyde-3-phosphate, ehydrogenase, ATP synthase subunit alpha, mitochondrial precursor, actin, aortic smooth muscle, 6- phosphofructokinase type C, 6-phosphofructokinase, muscle type, elongation factor 1-alpha 2, 2',3'-cyclic- nucleotide 3'-
			cytopiasinic 2, AP-2	phosphoulesterase, ATP

complex subunit beta

synthase subunit beta, mitochondrial precursor



Unique plasma and BH proteins between SiO₂&ZnO NPs

Plasma		Brain Homogenate			
SiO2	ZnO	SiO2	ZnO		
serum albumin precursor, histidine-rich glycoprotein, kininogen-1 isoform 2, apolipoprotein A- I preproprotein	fibrinogen gamma chain, fibrinogen beta chain precursor, gelsolin precursor	T-complex protein 1, 6- phosphofructokinas e	pyruvate kinase isozymes M1/M2, alpha-internexin, phosphoglycerate kinase 1		



Implicated biological processes by ZnO





Implicated biological processes by ZnO





Implicated biological processes by SiO_2 (+)







NF-*k*B implicated network



Complement component





Nanotoxocity based mitochondria dysfunction





Nanotoxocity based neurotransmitter





APOE and brain development





SiO_2 , 20/100 nm, (-) in vitro Study

- Cytotoxicity of SiO₂ with cell types as below
 - in vitro cellular models for Neuron, skin, GI tract were selected.

in vitro studies

- skin model: HDF human Dermal Fibroblast
- neuronal model: U373 human astrocyte/glioblastoma cell line
- GI tract model: HCT116 human colon carcinoma cell-line

Method

- Measuring cell viability after 24 hrs from treating cell with varying concentrations of $SiO_2^{20,(-)}$ & $SiO^{100,(-)}$
- Concentrations of ATP were measured for cell viability with luminescence-based assay, Cell-titerglo assay (Promega).



Cellular viability of Neuronal model





Cellular viability of skin model





Cellular viability of GI tract model





in vitro analysis of apoptosis

Poly (ADP-ribose) polymerase (PARP) cleavage

• Based on the results from celltiter-glo assay, predetermined and administered SiO₂^{100,(-)} 및 SiO₂^{20,(-)} and measured the cleavage of PARP from full-length 116kD to 89kDa (or 85kDa) at 0, 1, 3, 6, 9 hrs, with Anti-PARP antibody(cell signaling, Promega). Western Blot analyisis





in vitro analysis of apoptosis

DNA fragmentation : U373

- DNA fragmentations were analyzed by labeling fluorescence-labeled dUTP to the end of DNA with Terminal deoxynucleotidyl transferase.
- Method: DeadEnd[™] Fluorometric TUNEL System assay kit (Promega)







Neuroblastoma U373 cell viability was measured after 48 hrs from treatment with cell-titerglo assay.

80% of cell death were observed at 20ug/ml.









Activation of NF-kB by ZnO



After treating U373 cells with 20% (+) charged ZnO or 20% (-) charged ZnO. western blot analysis was performed to see the activation of NF-κB through IkBa After 15-30 min from treatment with ZnO (+), activation of IKK cause the lysis of IkBa. 45 min for ZnO (-) treatment.

¹****



Poly (ADP-ribose) polymerase (PARP) cleavage analysis after ZnO treatment on U373 cells

		20nm				100nm					
ZnO(-)	0	1	3	6	9	0	1	3	6	9	(hr)
PARP Cleaved form 85kDa	-	-	-	-	-			<u></u>	-	-	•
Tubulin	-					-		-	-		
			20nm	ı			1	00nm			
ZnO(+)	0	1	'n	6	9	0	1	'n	6		(hr)
	0	-	<u> </u>	-	-	· ·	-	<u> </u>	0	_	· · · · · ·
PARP Cleaved form 85kDa		1	- 13	P030	112	-	No.coa			-	•







in vivo study

28 days of repeated oral administration ($ZnO^{20,(+)}$, $ZnO^{20,(-)}$, $SiO_2^{20,(-)}$, $SiO_2^{20,Arg}$)

samples	NPs	sex	# animals	disage (mg/kg)	Conc. (mL/kg)
1 control	ddH2O	female	5	0	10
2. Buffer control	HEPES-Citrate Buffer	female	5	0	10
3 buffer control	HEPES-Serine Buffer	female	5	0	10
4 A.A control	L-arginine	female	5	0	10
5 High Conc.	ZnO ^{20,(-)} (20nm, - charge)	female	5	500	10
6 High Conc.	ZnO ^{20,(+)} (20nm, + charge)	female	5	500	10
7 High Conc.	SiO ₂ ^{20,(-)} (20nm, - charge)	female	5	2000	10
8 High Conc.	SiO ₂ ^{20,Arg} (20nm, - charge)	female	5	1000	10















Evans Blue analysis after 28days of ZnO^{20,(+)}, ZnO^{20,(-)} treatment

- After administration of 20 nm ZnO +, for 28 days, Rt, Lt brains and cerebellum were separated and evans blue (ug/g) was measured.
- Increased Evans blue was seen in all brain without significance.





Evans Blue analysis after 28days of ZnO^{20,(+)}, ZnO^{20,(-)} treatment

- After administration of 20 nm ZnO +, for 28 days, Rt, Lt and cerebellum were separated and evans blue (ug/g) was measured.
- Increased Evan's blue was seen in all brain without significance.





After 90 days of repeated treatments

route	NPs	disage (mg/kg)	Conc. (mL/kg)
orol	SiO ₂ ^{20,Arg} (20nm, negative charge)	1000	10
01 81	SiO ₂ ^{100,Arg} (100nm, negative charge)	1000	10
downol	SiO ₂ ^{20,(-)} (20nm, negative charge)	2000	10
dermal	SiO ₂ ^{100,(-)} (100nm, negative charge)	2000	10





TEM analysis: control





(A) SH-SY5Y neuroblastoma cells treated with SiO2ENB100,(–) (B) graph of energydispersive X-ray spectroscope analysis.



TEM analysis after 90 days of repeated SiO₂^{20,arg} [Cerebellum]





TEM analysis after 90 days of repeated SiO₂^{20,arg}[Hippocampus]

Hippocampus 1





TEM analysis after 90 days of repeated SiO₂^{20,arg}[Striatum]

Striatum 1





TEM analysis



(A–C) Dermally administered $SiO_2EN20(-)$ (D–F) dermally administered $SiO_2EN100(-)$



TEM analysis



(G–I) orally administered SiO₂EN20(R) (J–L) orally administered SiO₂EN100(R).



TEM analysis



The results of energy-dispersive X-ray spectroscope analysis of SiO₂EN20(.)-treated rat hippocampus via dermal administration.





TEM analysis



(A) Transmission electron microscope image of hippocampus in SiO₂100(–) dermal administration group
(P) enlarged image of suspected substance

- (B) enlarged image of suspected substance
- (C) graph of energy-dispersive X-ray spectroscope analysis.





- NPs need to be characterized prior to any experiments
- Diverse proteins were found in protein corona on NPs
- Smaller NPs revealed higher toxicity than the larger NPs
- NPs could cause apoptosis
- TEM imaging were used to search NPs in

brain, hippocampus, striatum, and cerebellum

• BBB seemed to be intact.



Q & A





THANK YOU!

